Ieq Capital LLC Takes Position in Bristol Myers Squibb Company $BMY

Key Points

• Ieq Capital LLC acquired 1.25 million Bristol Myers Squibb shares worth approximately $72.2 million, giving it a 0.06% stake. Institutional investors and hedge funds collectively own 76.41% of BMY.
• Bristol Myers Squibb reported stronger-than-expected quarterly results, with $2.04 in EPS and $12.97 billion in revenue, while revenue increased 5.7% year over year. Eliquis strength is helping offset generic pressure on older products, though portfolio erosion remains a key risk.
• The company is investing in long-term growth through a planned $2.3 billion Houston manufacturing facility and pipeline initiatives, including AI-driven antibody discovery and an early Alzheimer’s antibody study. Analysts maintain a “Moderate Buy” consensus with an average price target of $66.06, and BMY offers a 3.8% dividend yield.

Ieq Capital LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 1,252,740 shares of the biopharmaceutical company's stock, valued at approximately $72,183,000. Ieq Capital LLC owned approximately 0.06% of Bristol Myers Squibb as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BMY. Northwestern Mutual Investment Management Company LLC raised its holdings in Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company's stock worth $3,509,000 after buying an additional 172 shares during the last quarter. KCM Investment Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 0.8% during the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock valued at $1,126,000 after buying an additional 174 shares during the last quarter. Sandy Cove Advisors LLC increased its position in shares of Bristol Myers Squibb by 4.7% during the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after acquiring an additional 176 shares in the last quarter. Investment Research Partners LLC raised its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock worth $708,000 after acquiring an additional 179 shares during the last quarter. Finally, ESG Planning DBA Harper Investing lifted its position in Bristol Myers Squibb by 1.3% in the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company's stock valued at $745,000 after acquiring an additional 180 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $67.06 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company's 50 day moving average price is $60.55 and its two-hundred day moving average price is $59.37. The stock has a market cap of $136.98 billion, a P/E ratio of 14.77, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's revenue was up 5.7% on a year-over-year basis. During the same period last year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BMY shares. Royal Bank Of Canada boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a report on Friday, July 31st. Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the company an "equal weight" rating in a report on Friday, July 31st. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating for the company. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a research report on Friday, July 10th. Finally, Citigroup restated a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source